Evobrutinib

Progressive MS: emerging treatments 1:43
Progressive MS: emerging treatments
Emily Evans • 21 Feb 2023
Four-year efficacy and safety of evobrutinib for relapsing MS 2:30
Four-year efficacy and safety of evobrutinib for relapsing MS
Emily Evans • 21 Feb 2023
Review of BTK inhibition in MS 3:41
Review of BTK inhibition in MS
Shane Arsenault • 20 Feb 2023
The safety and efficacy of evobrutinib in multiple sclerosis 1:15
The safety and efficacy of evobrutinib in multiple sclerosis
Xavier Montalban • 8 Mar 2022
Prognostic value of baseline sNfL on treatment effect of evobrutinib 1:23
Prognostic value of baseline sNfL on treatment effect of evobrutinib
Jens Kuhle • 26 Jun 2022
BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis 3:51
BTK inhibitors: Investigating disease relevant mechanisms in multiple sclerosis
Rochelle Benoit • 28 Feb 2022
Potential of evobrutinib to target progressive MS 3:06
Potential of evobrutinib to target progressive MS
Jorge Alvarez • 25 Feb 2022
Assessing the interaction between blood NfL levels and BTK inhibitor efficacy in MS 1:08
Assessing the interaction between blood NfL levels and BTK inhibitor efficacy in MS
Jens Kuhle • 21 Oct 2021
The content of VJNeurology is intended for healthcare professionals